Clinical trial
Efficacy and Safety of Combination of Sorafenib as Preoperative Adjuvant and Latter Radiofrequency Ablation in the Treatment Of Recurrent Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study
NCT03097848 is registered in ClinicalTrials.gov with Southwest Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Combination of Sorafenib as Preoperative Adjuvant and Latter Radiofrequency Ablation in the Treatment Of Recurrent Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study
- Lead sponsor
- Southwest Hospital, China
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- May 4, 2017
- Completion date
- December 31, 2018
- Enrollment
- 450 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hcc